Pharmaceuticals, biotechnology and specialty ingredients manufacturer Lonza Group announced this week that Pierre-Alain Ruffieux officially started his new role as the company’s chief executive officer, replacing board chairman Albert M. Baehny who served as CEO ad interim over the last year. Ruffieux was appointed to the position last June.
“I would like to extend a warm welcome to Pierre-Alain as he joins the Lonza family. He brings with him more than two decades of industry experience and an outstanding track record of professional achievement in both scientific and manufacturing excellence,” said Baehny in a company release. “He combines this deep industry knowledge with a clear understanding of Lonza’s unique position in the market. His experience and expertise will prove invaluable as Lonza Group continues to drive ambitious growth levels and capitalzize on its positon as a leading manufacturing partner in the pharma and biotech industry.”
Baehny will work with Ruffieux during the leadership transition prior to resuming his role as chairman of the board of directors. Ruffieux most recently served as Head of Global Pharma Technical Operations at Roche, leading pharmaceutical commercial manufacturing and supply chain operations.
“I am very pleased to commence my tenure as CEO of Lonza Group. I have had theopportunity to work with Lonza as a customer many times in my career to date, so I know both the strength and value of this enterprise, its technology and its people. I hope my experience as a customer will give me a unique perspective on how Lonza can develop its world class service offering in the coming years,” said Pierre-Alain Ruffieux in a statement.
Lonza initiated a search for a new CEO in December 2019 as then-CEO Marc Funk was preparing to step down from his position for “personal reasons,” Powder & Bulk Solids reported.